Peptide LexiconAll compounds

Prostamax (Lys-Glu-Asp-Pro): The 'Prostate Bioregulator' Whose Five PubMed Records Are All About Chromatin

Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro, a short 'bioregulator' from the St Petersburg peptide programme, sold for the prostate. PubMed holds five records naming it, from 2004 to 2012. Every one studies chromatin in blood cells or tissue cultures; none studies the prostate in a person, and no trial is registered.

Not approved anywhere this entry foundNo registered trialNo prostate study in people

Caroline S · Published 2026-11-17

Length

4 amino acids — C20H33N5O9, molecular weight about 487.5 (our calculation from the sequence; PubChem returns no record for the name)

Sequence

KEDP (Lys-Glu-Asp-Pro), as given in the title of PMID 23221144

Origin

Synthetic; one of the short peptides of the St Petersburg bioregulator series associated with V. Khavinson

Last reviewed

2026-11-17

What is it good for?

Sellers present it as a bioregulator for the prostate and for ageing men. No published study tests that. The five PubMed records that name it measure chromatin — how tightly DNA is packed — in blood lymphocytes from elderly people and in rat tissue cultures. None reports a prostate outcome, a symptom, or a controlled trial in people.

Illustration: A white molecular model of a tetrapeptide on a white surface with a deep green background and copper.
Illustration

What it is

Prostamax is a synthetic peptide of four amino acids: lysine, glutamic acid, aspartic acid and proline. A 2012 paper gives the sequence in its title — "oligopeptide bioregulator (Lys-Glu-Asp-Pro)" (Dzhokhadze et al., PMID 23221144). It is one of the short peptides of the St Petersburg bioregulator series, each named for an organ; this one is named for the prostate.

Property Value Source
Sequence Lys-Glu-Asp-Pro (KEDP) PMID 23221144, title
Length 4 amino acids —
Formula C20H33N5O9 Our calculation from the sequence
Molecular weight about 487.5 Our calculation
PubChem record None found for "prostamax" or "Lys-Glu-Asp-Pro" PubChem, 2026-11-17

The family resemblance is in the letters. The library's Vilon entry is Lys-Glu; Vesugen is Lys-Glu-Asp; the heart-labelled Cardiogen is a different four-letter chain, AEDR; Prostamax adds a proline to Vesugen's three to make Lys-Glu-Asp-Pro. Each is sold for a different organ. The 2004 chromatin study below also tested Cortagen, the series' brain-cortex peptide, which differs from Prostamax only in its first amino acid.

What PubMed holds — and what it does not

A search of titles and abstracts on 2026-11-17 returned five records, from 2004 to 2012. Read one by one:

Year Journal What was studied People given the peptide?
2004 Bull Exp Biol Med (PMID 15085253) Leukocytes from people aged 75–88, treated in the laboratory with Vilon, Epithalon, Livagen, Prostamax and Cortagen No
2004 Biofizika (PMID 15612551) Heat-melting behaviour of chromatin in human lymphocytes treated with Prostamax No
2006 Adv Gerontol (PMID 17152728) Synthetic peptides in organ-type tissue cultures from young and old rats (title) No
2009 Georgian Med News (PMID 19359734) Heat output of lymphocyte cultures with copper, cadmium and Prostamax (title) No
2012 Georgian Med News (PMID 23221144) Chromosome markers in cells from people aged 75–86 No

The finding nobody selling it states: not one of the five records is about the prostate. Every study measures chromatin — how tightly DNA is wound in the nucleus — or the physical behaviour of cells in a dish. The two records whose titles alone were read (2006, 2009) are also laboratory work.

The 2012 study reports what the peptide changed in cells from people aged 75 to 86: sister chromatid exchanges rose to 12.0 per cell from 5.9, active ribosomal-gene regions (Ag-NORs) to 2.5 per cell from 0.95, and large blocks of condensed chromatin on chromosomes 1 and 9 became less frequent. The authors interpret this as Prostamax "decondensing" chromatin and releasing genes switched off in ageing.

The 2004 Bulletin study compared five peptides on leukocytes from people aged 75 to 88 and reports that all five activated ribosomal genes; Epithalon, Livagen and Prostamax also decondensed the structural chromatin around the centre of chromosome 1.

What is not established

  • Any effect on the prostate. No record names a prostate measurement, a urinary symptom or a hormone level.
  • Any effect in a living person. Every human sample was blood cells treated outside the body.
  • Independent replication. The 2004 Bulletin study comes from the St Petersburg Institute of Bioregulation and Gerontology, and T. Lezhava is an author on four of the five records; the fifth (2006, rat tissue cultures) lists a different team. No independent group has reported a study in people.
  • Safety. No study reports giving it to anyone, so nothing is known about safety in people.

ClinicalTrials.gov lists no study of Prostamax (2026-11-17; a control search for semaglutide the same day returned 836).

Where it stands

Prostamax is an unapproved research peptide with a small laboratory literature on chromatin and none on its namesake organ. Questions about prostate symptoms belong to a doctor; the library records what the compound is and what has been measured.

Sources opened 2026-11-17: PubMed E-utilities (search and the five records: abstracts of PMIDs 23221144, 15085253, 15612551; titles of 17152728, 19359734); PubChem name search; ClinicalTrials.gov API v2.

What the research shows

Supports prostate health

No study found. PubMed: 0 of the 5 records naming prostamax report a prostate outcome in people (2026-11-17)

Unpacks condensed chromatin in elderly people's cells

Khavinson, Lezhava and Malinin 2004, Bull Exp Biol Med (PMID 15085253): leukocytes from people aged 75–88, treated in the laboratory with five peptides; Prostamax among those that decondensed chromosome 1 heterochromatin

Changes chromosome markers in old age

Dzhokhadze et al. 2012, Georgian Med News (PMID 23221144): cells from people aged 75–86; sister chromatid exchanges 12.0 per cell vs 5.9 untreated

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Approved as a medicine

No approval found. Drugs@FDA and the indexed papers name none, and PubChem returns no record for 'prostamax' or 'Lys-Glu-Asp-Pro' (2026-11-17).

Trials

ClinicalTrials.gov: 0 studies for 'prostamax' (2026-11-17; a control search for semaglutide the same day returned 836).

Published record

PubMed: 5 records with 'prostamax' in the title or abstract, 2004–2012; 0 tagged as randomised controlled trials (2026-11-17).

Frequently asked questions

What is Prostamax?

A synthetic peptide of four amino acids — lysine, glutamic acid, aspartic acid and proline, written Lys-Glu-Asp-Pro or KEDP. It belongs to the St Petersburg series of short peptide 'bioregulators'.

What is Prostamax said to be good for?

Sellers present it for the prostate and for ageing in men. No published study tests either: the five PubMed records naming it look at chromatin in blood cells and tissue cultures, not at the prostate in people.

Has Prostamax been tested in humans?

Not as a treatment. Two studies used blood cells taken from elderly people and exposed them to the peptide in the laboratory. No one was given Prostamax, and no trial is registered on ClinicalTrials.gov.

Is Prostamax the same as Vesugen?

No, though they are close. Vesugen is the tripeptide Lys-Glu-Asp. Prostamax has one more amino acid, proline, on the end: Lys-Glu-Asp-Pro.

Is Prostamax approved?

No approval turned up in any source checked, and no indexed paper claims one. It reaches buyers as a research peptide or in prostate-themed bioregulator blends; this library describes the compound, not those products.

Does Prostamax act on genes?

The papers report changes in how tightly chromatin is packed in treated cells, and the authors read that as releasing repressed genes. That is an interpretation of laboratory measurements; no study links it to any effect in a person.